Hansa Biopharma expands the leadership team with the appointment of Katja Margell as new Head of Corporate Communications
Lund, Sweden July 16, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company has appointed Katja Margell as new Head of Corporate Communications.
Katja brings extensive corporate communications experience as a former partner at Swedish communications agencies Kreab Worldwide and Hallvarsson & Halvarsson where she focused on strategic, corporate and capital markets communication. Prior to this, Katja was Group Communications Manager at Swedish bank SEB and has also held positions within communications and investor relations in companies in the life science sector. Katja holds double Master’s degrees in laws from Vrije Universiteit Brussels and Stockholms University, and she has a background in journalism.
“Katja brings extensive corporate communications experience from leading communications agencies and companies and will be a great addition to the Hansa team as the Company transitions into a commercial stage biopharmaceutical company and expands its proprietary enzyme technology platform beyond transplantation”, says Søren Tulstrup, President & CEO of Hansa Biopharma.
Katja will assume the role as Head of Corporate Communications with immediate effect.
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Mobile: +46 (0) 709-298 269
Katja Margell, Head of Corporate Communications
Mobile: +46 (0) 768-198 326